These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25691428)

  • 1. Research delves into role of key proteins in fragile X syndrome: study explores relationship between enzymes, FXS symptoms; identifies candidate drug for targeted treatment.
    Levenson D
    Am J Med Genet A; 2015 Mar; 167A(3):ix. PubMed ID: 25691428
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacogenetic inhibition of eIF4E-dependent Mmp9 mRNA translation reverses fragile X syndrome-like phenotypes.
    Gkogkas CG; Khoutorsky A; Cao R; Jafarnejad SM; Prager-Khoutorsky M; Giannakas N; Kaminari A; Fragkouli A; Nader K; Price TJ; Konicek BW; Graff JR; Tzinia AK; Lacaille JC; Sonenberg N
    Cell Rep; 2014 Dec; 9(5):1742-1755. PubMed ID: 25466251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reducing eIF4E-eIF4G interactions restores the balance between protein synthesis and actin dynamics in fragile X syndrome model mice.
    Santini E; Huynh TN; Longo F; Koo SY; Mojica E; D'Andrea L; Bagni C; Klann E
    Sci Signal; 2017 Nov; 10(504):. PubMed ID: 29114037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase-9 deletion rescues auditory evoked potential habituation deficit in a mouse model of Fragile X Syndrome.
    Lovelace JW; Wen TH; Reinhard S; Hsu MS; Sidhu H; Ethell IM; Binder DK; Razak KA
    Neurobiol Dis; 2016 May; 89():126-35. PubMed ID: 26850918
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin ameliorates core deficits in a mouse model of fragile X syndrome.
    Gantois I; Khoutorsky A; Popic J; Aguilar-Valles A; Freemantle E; Cao R; Sharma V; Pooters T; Nagpal A; Skalecka A; Truong VT; Wiebe S; Groves IA; Jafarnejad SM; Chapat C; McCullagh EA; Gamache K; Nader K; Lacaille JC; Gkogkas CG; Sonenberg N
    Nat Med; 2017 Jun; 23(6):674-677. PubMed ID: 28504725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. R-Baclofen Reverses a Social Behavior Deficit and Elevated Protein Synthesis in a Mouse Model of Fragile X Syndrome.
    Qin M; Huang T; Kader M; Krych L; Xia Z; Burlin T; Zeidler Z; Zhao T; Smith CB
    Int J Neuropsychopharmacol; 2015 Mar; 18(9):. PubMed ID: 25820841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular and cellular aspects of mental retardation in the Fragile X syndrome: from gene mutation/s to spine dysmorphogenesis.
    De Rubeis S; Fernández E; Buzzi A; Di Marino D; Bagni C
    Adv Exp Med Biol; 2012; 970():517-51. PubMed ID: 22351071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragile X mental retardation protein: A paradigm for translational control by RNA-binding proteins.
    Chen E; Joseph S
    Biochimie; 2015 Jul; 114():147-54. PubMed ID: 25701550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Melatonin as a Novel Interventional Candidate for Fragile X Syndrome with Autism Spectrum Disorder in Humans.
    Won J; Jin Y; Choi J; Park S; Lee TH; Lee SR; Chang KT; Hong Y
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28632163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the Understanding of the Gabaergic Neurobiology of FMR1 Expanded Alleles Leading to Targeted Treatments for Fragile X Spectrum Disorder.
    Lozano R; Martinez-Cerdeno V; Hagerman RJ
    Curr Pharm Des; 2015; 21(34):4972-4979. PubMed ID: 26365141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fragile X syndrome neurobiology translates into rational therapy.
    Braat S; Kooy RF
    Drug Discov Today; 2014 Apr; 19(4):510-9. PubMed ID: 24508819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The quest for targeted therapy in fragile X syndrome.
    Zeidler S; Hukema RK; Willemsen R
    Expert Opin Ther Targets; 2015; 19(10):1277-81. PubMed ID: 26294013
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic reduction of MMP-9 in the Fmr1 KO mouse partially rescues prepulse inhibition of acoustic startle response.
    Kokash J; Alderson EM; Reinhard SM; Crawford CA; Binder DK; Ethell IM; Razak KA
    Brain Res; 2019 Sep; 1719():24-29. PubMed ID: 31128097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based treatments in neurodevelopmental disorders: fragile X syndrome.
    Berry-Kravis E
    Pediatr Neurol; 2014 Apr; 50(4):297-302. PubMed ID: 24518745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BDNF in fragile X syndrome.
    Castrén ML; Castrén E
    Neuropharmacology; 2014 Jan; 76 Pt C():729-36. PubMed ID: 23727436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular medicine of fragile X syndrome: based on known molecular mechanisms.
    Luo SY; Wu LQ; Duan RH
    World J Pediatr; 2016 Feb; 12(1):19-27. PubMed ID: 26547211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological Treatments for Fragile X Syndrome Based on Synaptic Dysfunction.
    Telias M
    Curr Pharm Des; 2019; 25(41):4394-4404. PubMed ID: 31682210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacotherapy for Fragile X Syndrome: Progress to Date.
    Davenport MH; Schaefer TL; Friedmann KJ; Fitzpatrick SE; Erickson CA
    Drugs; 2016 Mar; 76(4):431-45. PubMed ID: 26858239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders.
    Gantois I; Popic J; Khoutorsky A; Sonenberg N
    Annu Rev Med; 2019 Jan; 70():167-181. PubMed ID: 30365357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model.
    Bilousova TV; Dansie L; Ngo M; Aye J; Charles JR; Ethell DW; Ethell IM
    J Med Genet; 2009 Feb; 46(2):94-102. PubMed ID: 18835858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.